Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data show that imatinib treatment may promote the development of anti-leukemia...
Enregistré dans:
Auteurs principaux: | Peter S Kim, Peter P Lee, Doron Levy |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7808c811147148829caaa39e2e938d5c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Bosutinib in the management of chronic myelogenous leukemia
par: Keller-von Amsberg G, et autres
Publié: (2013) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
par: Harnicar S, et autres
Publié: (2014) -
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
par: Maiko Matsushita
Publié: (2021) -
Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML).
par: Young Kwang Chae, et autres
Publié: (2008) -
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells
par: Yan Xu, et autres
Publié: (2018)